The prevalence of acute response to bronchodilator in pulmonary lymphangioleiomyomatosis

Kenneth T. Yen, John D. Putzke, Bruce A. Staats, Charles Dwayne Burger

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objective: The objective of this study was to evaluate the prevalence of acute bronchodilator responses in patients who were evaluated for pulmonary lymphangioleiomyomatosis. Methodology: This study was a retrospective review of the medical records of 50 patients, who were assessed for lymphangioleiomyomatosis from 1978 to 2002 at Mayo Clinic in Rochester, Minnesota, and Jacksonville, Florida, USA. Each medical record was reviewed for pertinent clinical and pulmonary function test data, including results for lung volume and flow, diffusing capacity and response to bronchodilator. Results: At initial testing, the mean FEV1/FVC ratio for the whole group was 60%; 35 patients (70%) had airflow obstruction; five patients (10%) had only restriction; and 10 (20%) had neither restriction nor obstruction. Three patients (6%) showed a positive response to bronchodilator at initial testing and only one patient showed a positive response at 1 year. Pulmonary function testing at 1-year follow up was available in a subgroup of this cohort (23 patients; 46%), and only one patient (2%) had a positive response to bronchodilator. Although there was a statistically significant decrease in the FEV1/FVC ratio (from 64% to 62%; P = 0.02), no other differences were found at 1-year follow up. Conclusions: In its advanced state, lymphangioleiomyomatosis produces irreversible airflow obstruction. A positive response to bronchodilator was unusual. Other measures of pulmonary function showed little or no change over a 12-month period.

Original languageEnglish (US)
Pages (from-to)643-648
Number of pages6
JournalRespirology
Volume10
Issue number5
DOIs
StatePublished - Nov 2005

Fingerprint

Lymphangioleiomyomatosis
Bronchodilator Agents
Lung
Medical Records
Respiratory Function Tests

Keywords

  • Bronchodilators
  • Chronic airflow obstruction
  • Lung diseases
  • Lymphangioleiomyomatosis
  • Retrospective studies

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

The prevalence of acute response to bronchodilator in pulmonary lymphangioleiomyomatosis. / Yen, Kenneth T.; Putzke, John D.; Staats, Bruce A.; Burger, Charles Dwayne.

In: Respirology, Vol. 10, No. 5, 11.2005, p. 643-648.

Research output: Contribution to journalArticle

Yen, Kenneth T. ; Putzke, John D. ; Staats, Bruce A. ; Burger, Charles Dwayne. / The prevalence of acute response to bronchodilator in pulmonary lymphangioleiomyomatosis. In: Respirology. 2005 ; Vol. 10, No. 5. pp. 643-648.
@article{7c4f366ac07a4a2b9d020a7c44290e84,
title = "The prevalence of acute response to bronchodilator in pulmonary lymphangioleiomyomatosis",
abstract = "Objective: The objective of this study was to evaluate the prevalence of acute bronchodilator responses in patients who were evaluated for pulmonary lymphangioleiomyomatosis. Methodology: This study was a retrospective review of the medical records of 50 patients, who were assessed for lymphangioleiomyomatosis from 1978 to 2002 at Mayo Clinic in Rochester, Minnesota, and Jacksonville, Florida, USA. Each medical record was reviewed for pertinent clinical and pulmonary function test data, including results for lung volume and flow, diffusing capacity and response to bronchodilator. Results: At initial testing, the mean FEV1/FVC ratio for the whole group was 60{\%}; 35 patients (70{\%}) had airflow obstruction; five patients (10{\%}) had only restriction; and 10 (20{\%}) had neither restriction nor obstruction. Three patients (6{\%}) showed a positive response to bronchodilator at initial testing and only one patient showed a positive response at 1 year. Pulmonary function testing at 1-year follow up was available in a subgroup of this cohort (23 patients; 46{\%}), and only one patient (2{\%}) had a positive response to bronchodilator. Although there was a statistically significant decrease in the FEV1/FVC ratio (from 64{\%} to 62{\%}; P = 0.02), no other differences were found at 1-year follow up. Conclusions: In its advanced state, lymphangioleiomyomatosis produces irreversible airflow obstruction. A positive response to bronchodilator was unusual. Other measures of pulmonary function showed little or no change over a 12-month period.",
keywords = "Bronchodilators, Chronic airflow obstruction, Lung diseases, Lymphangioleiomyomatosis, Retrospective studies",
author = "Yen, {Kenneth T.} and Putzke, {John D.} and Staats, {Bruce A.} and Burger, {Charles Dwayne}",
year = "2005",
month = "11",
doi = "10.1111/j.1440-1843.2005.00762.x",
language = "English (US)",
volume = "10",
pages = "643--648",
journal = "Respirology",
issn = "1323-7799",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - The prevalence of acute response to bronchodilator in pulmonary lymphangioleiomyomatosis

AU - Yen, Kenneth T.

AU - Putzke, John D.

AU - Staats, Bruce A.

AU - Burger, Charles Dwayne

PY - 2005/11

Y1 - 2005/11

N2 - Objective: The objective of this study was to evaluate the prevalence of acute bronchodilator responses in patients who were evaluated for pulmonary lymphangioleiomyomatosis. Methodology: This study was a retrospective review of the medical records of 50 patients, who were assessed for lymphangioleiomyomatosis from 1978 to 2002 at Mayo Clinic in Rochester, Minnesota, and Jacksonville, Florida, USA. Each medical record was reviewed for pertinent clinical and pulmonary function test data, including results for lung volume and flow, diffusing capacity and response to bronchodilator. Results: At initial testing, the mean FEV1/FVC ratio for the whole group was 60%; 35 patients (70%) had airflow obstruction; five patients (10%) had only restriction; and 10 (20%) had neither restriction nor obstruction. Three patients (6%) showed a positive response to bronchodilator at initial testing and only one patient showed a positive response at 1 year. Pulmonary function testing at 1-year follow up was available in a subgroup of this cohort (23 patients; 46%), and only one patient (2%) had a positive response to bronchodilator. Although there was a statistically significant decrease in the FEV1/FVC ratio (from 64% to 62%; P = 0.02), no other differences were found at 1-year follow up. Conclusions: In its advanced state, lymphangioleiomyomatosis produces irreversible airflow obstruction. A positive response to bronchodilator was unusual. Other measures of pulmonary function showed little or no change over a 12-month period.

AB - Objective: The objective of this study was to evaluate the prevalence of acute bronchodilator responses in patients who were evaluated for pulmonary lymphangioleiomyomatosis. Methodology: This study was a retrospective review of the medical records of 50 patients, who were assessed for lymphangioleiomyomatosis from 1978 to 2002 at Mayo Clinic in Rochester, Minnesota, and Jacksonville, Florida, USA. Each medical record was reviewed for pertinent clinical and pulmonary function test data, including results for lung volume and flow, diffusing capacity and response to bronchodilator. Results: At initial testing, the mean FEV1/FVC ratio for the whole group was 60%; 35 patients (70%) had airflow obstruction; five patients (10%) had only restriction; and 10 (20%) had neither restriction nor obstruction. Three patients (6%) showed a positive response to bronchodilator at initial testing and only one patient showed a positive response at 1 year. Pulmonary function testing at 1-year follow up was available in a subgroup of this cohort (23 patients; 46%), and only one patient (2%) had a positive response to bronchodilator. Although there was a statistically significant decrease in the FEV1/FVC ratio (from 64% to 62%; P = 0.02), no other differences were found at 1-year follow up. Conclusions: In its advanced state, lymphangioleiomyomatosis produces irreversible airflow obstruction. A positive response to bronchodilator was unusual. Other measures of pulmonary function showed little or no change over a 12-month period.

KW - Bronchodilators

KW - Chronic airflow obstruction

KW - Lung diseases

KW - Lymphangioleiomyomatosis

KW - Retrospective studies

UR - http://www.scopus.com/inward/record.url?scp=33644843695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644843695&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1843.2005.00762.x

DO - 10.1111/j.1440-1843.2005.00762.x

M3 - Article

C2 - 16268919

AN - SCOPUS:33644843695

VL - 10

SP - 643

EP - 648

JO - Respirology

JF - Respirology

SN - 1323-7799

IS - 5

ER -